Apparently, South Korea’s Ministry of Food and Drug Safety (MFDS) is to lessen the patient’s financial burden through a patient aid program for a rare cancer treatment Lutathera until it gets officially listed for reimbursement. The government program would grant a free dose of the treatment.

MFDS announced the Lutathera patient aid program would run for 12 months as collaborated by Korea Orphan & Essential Drug Center (KOEDC, CEO Kim Nakyung), a foreign drug developer with an Advanced Accelerator Application, and Korea Alliance of Patients Organization (KAPO).

Lutathera is indicated to treat patients with neuroendocrine tumor, which costs approximately 100 million won for a single t